- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 22.10. | SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S. | 327 | Business Wire | Orthofix is a global medical technology company focused on healing musculoskeletal pathologies The distribution arrangement is part of SMAIO's collaborative strategy aimed at deploying... ► Artikel lesen | |
| 17.10. | SMAIO H1 Sales Increase | 1 | RTTNews | ||
| 14.10. | SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025 | 194 | Business Wire | Strong sales growth in H1 2025: +126% to €5.0 million
Increase in gross margin in H1 2025 to 85% vs. 64% in H1 2024
Significant improvement in EBITDA (+96%) reaching break-even (vs.... ► Artikel lesen | |
| 24.09. | SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S. | 276 | Business Wire | Highridge Medical is one of the world's largest privately held spine companies The partnership represents a key milestone in further expanding SMAIO's business activity in the U.S. and driving... ► Artikel lesen | |
| 16.07. | SMAIO Announces Significant Sales Increase in H1 2025 | 298 | Business Wire | Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million):
H1 2025 sales1 higher than full-year 2024 sales
More than... ► Artikel lesen | |
| 12.05. | SMAIO Announces the Finalization of a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 364 | Business Wire | The transaction was fully subscribed by NextStage AM, in accordance with the terms previously communicated
Regulatory News:
This press release may not be published, distributed or disseminated... ► Artikel lesen | |
| 15.04. | SMAIO Announces a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 521 | Business Wire | Regulatory News:
This press release may not be published, distributed or disseminated, directly or indirectly, in the United States of America or Canada, Australia, Japan or South Africa.
SMAIO... ► Artikel lesen | |
| 15.04. | SMAIO Announces Consolidated Results for 2024 and Record Sales Performance in Q1 2025 | 393 | Business Wire | Sharp increase in sales, up +114%1 to €5.5 million in 2024 and +140% to €2.5 million in Q1 2025
Improvement in the margin rate on implant sales to 79% in 2024, vs. 71% at the end of 2023... ► Artikel lesen | |
| 28.02. | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 481 | Business Wire | Appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke's Clinic in Boise (Idaho) SMAIO's U.S. scientific advisory board now includes three North American surgeons, and is set... ► Artikel lesen | |
| 27.01. | SMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. Market | 300 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 21.01. | SMAIO Announces 2024 Sales of €5.5m, More Than Half of Which Generated in the United States | 522 | Business Wire | Implant sales growth in excess of 100%, thanks to a strategic focus on the US market, driving strong revenue growth which is now mainly generated in the United States Establishment of the Group's... ► Artikel lesen | |
| 06.01. | SMAIO: 2025 Financial Calendar | 352 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris ISIN: FR0014005I80 Ticker: ALSMA, PEA-PME eligible), a French player specialized in complex... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 49,510 | -1,02 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 48,740 | +0,35 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 16,870 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,430 | -0,28 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | 0,00 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| GERRESHEIMER | 27,340 | -0,94 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| UNITEDHEALTH | 296,00 | +0,61 % | Earnings Preview - Teil 1: Make or Break für den Markt: Die Zahlen von UnitedHealth, Microsoft & Alphabet! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW44) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| BUTTERFLY NETWORK | 2,695 | 0,00 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | 0,00 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 44,060 | +0,36 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Carl Zeiss Meditec mit einem Kursziel von 35,10 Euro auf "Underweight" belassen. Vor den am 11. Dezember anstehenden Quartalszahlen lägen seine... ► Artikel lesen | |
| BETA BIONICS | 27,210 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | 0,00 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,280 | 0,00 % | Privia Health Group, Inc. - 8-K, Current Report |
Das Unternehmen S.M.A.I.O SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 6,400 Euro und damit -0,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu S.M.A.I.O SA finden Sie auf Wallstreet Online.